Toxicological Research

  • 제29권1호
  • /
  • Pages.27-34
  • /
  • 2013
  • /
  • 1976-8257(pISSN)
  • /
  • 2234-2753(eISSN)
한국독성학회 (Korean Society of Toxicology & Korea Environmental Mutagen Society)
권호 표지
DOI QR코드

DOI QR Code

Embryotoxicity and Toxicokinetics of the Antimalarial Artesunate in Rats

  • 투고 : 2012.10.31
  • 심사 : 2013.01.24
  • 발행 : 2013.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

This study was conducted to investigate the potential embryo-fetal toxicity and toxicokinetics of the antimalarial agent artesunate (ARTS) in Sprague-Dawley rats. Pregnant rats were administered ARTS daily from gestational day 6~15 via oral gavage, at test doses of 0, 2, 4, or 8 mg/kg (22 females per group). The fetuses were examined for external, visceral, and skeletal abnormalities on gestational day 20. With regard to the dams, there were no deaths, treatment-related clinical signs, changes in body weight, or food intake in any of the treatment groups. There were no treatment-related gross findings at necropsy in any treatment group. In the 8 mg/kg group, there was a decrease in gravid uterine weight and in the weight of female fetuses. There was also an increase in fetal deaths (primarily late resorptions) and an increase in post-implantation losses (37%) at 8 mg/kg. An increase in the incidence of visceral and skeletal variations at 4 and 8 mg/kg was observed. These defects included minor changes in the appearance of the kidney and thymus, as well as absent ribs or thoracic vertebrae. Toxicokinetics were assessed in a parallel study, using 4 mated females per group. Using liquid chromatography-mass spectrometry (LC-MS) analysis, the concentration of ARTS and its metabolite dihydroartemisinin (DHA) were quantified in plasma from rats on gestational days 5, 6, 10, and 15. Amniotic fluid was assayed for ARTS and DHA on gestational day 15. There was evidence of rapid conversion of ARTS to the metabolite DHA in maternal plasma, since ARTS could not be consistently detected in plasma at the three doses tested. ARTS and DHA were not detected in amniotic fluid at gestational day 15, indicating limited placental transfer of the two agents. The embryo-fetal no-observable-adverse-effect level (NOAEL) of the test item was considered to be 8 mg/kg/day for dams, and 2 mg/kg/day for embryo-fetal development.

키워드

참고문헌

  1. Bialek, R. and Knobloch, J. (1999) Parasitic diseases in pregnancy and congenital parasitos. Part 1. Protozoan infections (Review, German). Z Geburthilfe Neonatal., 203, 55-62.
  2. Deen, J.L., von Seidlein, L., Pinder, M., Welraven, G.E. and Greenwood, B.M. (2001) The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans. R. Soc. Trop. Med. Hyg., 95, 424-428. https://doi.org/10.1016/S0035-9203(01)90204-4
  3. White, N.J., Nosten, F., Looareesuwan, S., Watkins, W.M., Marsh, K., Snow, R.W., Kokwaro, G., Ouma, J., Hien, T.T., Molyneux, M.E., Taylor, T.E., Newbold, C.I., Ruebush T.K. 2nd., Danis, M., Greenwood, B.M., Anderson, R.M. and Olliaro, P. (1999) Averting a malaria disaster. Lancet, 353, 1965-1967. https://doi.org/10.1016/S0140-6736(98)07367-X
  4. Ilett, K.F., Batty, K.T., Powell, S.M., Binh, T.Q., Thu le, T.A., Phuong, H.L., Hung, N.C. and Davis, T.M. (2002) The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol., 53, 23-30. https://doi.org/10.1046/j.0306-5251.2001.01519.x
  5. Sarciron, M.E., Saccharin, C., Petavy, A.F. and Peyron, F. (2000) Effect of artesunate, dihydroartemisinin, and an artesunate- dihyroartemisinin combination against Toxoplasma gondii. Am. J. Trop. Med. Hyg., 62, 73-76.
  6. Barradell, L.B. and Fitton, A. (1995) Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs, 50, 714-741. https://doi.org/10.2165/00003495-199550040-00009
  7. Luzzi, G.A. and Peto, T.E. (1993) Adverse effects of antimalarials: An update. Drug Saf., 8, 295-311. https://doi.org/10.2165/00002018-199308040-00004
  8. Motta, M., Tincani, A., Faden, D., Zinzini, E. and Chirco, G. (2002) Antimalarial agents in pregnancy. Lancet, 359, 524-525.
  9. Clark, R.L., White, T.E., A Clode, S., Gaunt, I., Winstanley, P. and Ward, S.A. (2004) Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res. Part B, 71, 380-394 https://doi.org/10.1002/bdrb.20027
  10. Dawson, A.B. (1926) A note on the staining of the skeleton of cleared specimens with Alizarin Red S. Stain. Technol., 1, 123-124.
  11. Wilson, J.G. (1965) Methods for administering agents and detecting malformations in experimental animals. In: Teratology, Principles and Techniques, Wilson, J.G. and Warkany, J. ed., University of Chicago press, Chicago and London, pp. 262-277.
  12. Nishimura, K. (1974) A microdissection method for detecting thoracic visceral malformations in mouse and rat fetuses. Cong. Anom., 14, 23-40.
  13. Makris, S.L., Solomon, H.M., Clark, R., Shiota, K., Barbellion, S., Buschmann, J., Ema, M., Fujiwara, M., Grote, K., Hazelden, K.P., Hew, K.W., Horimoto, M., Ooshima, Y., Parkinson, M. and Wise, L.D. (2009) Terminology of developmental abnormalities in common laboratory mammals (Version 2). Birth Defects Res. Part B, 86, 227-327. https://doi.org/10.1002/bdrb.20200
  14. Naik, H., Murry, D.J., Kirsch, LE. and Fleckenstein, L. (2005) Development and validation of a high-performance liquid chromatography-mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 816, 233-242. https://doi.org/10.1016/j.jchromb.2004.11.042
  15. MARTA. (1997) Appendix B: Historical Control Data. In: Handbook of Developmental Toxicology (Hood RD, ed). CRC Press, New York, pp. 716-724.
  16. Chahoud, I., Ligensa, A., Dietzel, L. and Faqi, A.S. (1999) Correlation between maternal toxicity and embryo/fetal effects. Reprod. Toxicol., 13, 375-381. https://doi.org/10.1016/S0890-6238(99)00035-0
  17. White, T.E.K., Chadderton, A.R., Bushdid, P.B., Vidal, J.D. and Clark, R.L. (2005) Early artesunate-induced changes in the rat embryo preceding embryolethality and embryotoxicity. Birth Defects Res. Part B, 73, 297-310.
  18. Meshnick, S.R. (2002) Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol., 32, 1655-1660. https://doi.org/10.1016/S0020-7519(02)00194-7
  19. Li, Q. and Weina, P.J. (2010) Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women. Mol., 15, 40-57.

피인용 문헌

  1. Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification vol.4, pp.1, 2016, https://doi.org/10.1186/s40364-016-0077-0
  2. Treatment of Murine Cerebral Malaria by Artemisone in Combination with Conventional Antimalarial Drugs: Antiplasmodial Effects and Immune Responses vol.58, pp.8, 2014, https://doi.org/10.1128/AAC.01553-13